A first-generation CAR directed against carboxy-anhydrase-IX (CAIX), a highly expressed enzyme in RCC, was studied in a phase I/II trial, where 12 patients with previously treated mRCC received a maximum of 10 daily CAR-T infusions. The gene discussed is CA9; the disease is renal cell carcinoma.